Although the numbers investigated in each group were small, there appeared to be a dominant response to BMI-1 in the patients with colorectal and prostate cancer, whereas stronger reactivity to EZH2 was more common among the HCC patients. This evidence concerns the gene EZH2 and hepatocellular carcinoma.